RxDoctor Payments Data

Robert Parris, MD

Cardiovascular Disease · Fort Smith, ARNPI 1043253511

Payments from drug & device makers

What this record shows

21 manufacturers reported payments, led by Boston Scientific at 39.0% of the total. Reporting peaked in 2023 at $5,574 and has fallen 66.8% since, to $1,853 in 2025.

$12,720in general payments, 2019–2025

Across 283 payments — averaging $44.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$5K
  • Medtronic$4K
  • Abiomed$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$647
  • E.r. Squibb & Sons, L.L.C.$430
  • Johnson & Johnson$363
  • plus $1K from 15 others

What the payments were for

  • Travel & lodging$6,48951%
  • Food & beverage$6,23149%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,720 in reported general payments places this provider in the 80th percentile of 130 cardiovascular disease providers in Arkansas.

See all cardiovascular disease providers in Arkansas

Medicare billing

Part B allowed, 2024
$363,517
Medicare patients
2,065
Services billed
7,983

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban742$589,997
EntrestoSacubitril/Valsartan329$305,481
XareltoRivaroxaban267$258,366
BrilintaTicagrelor139$99,042
MultaqDronedarone Hcl89$91,648
JardianceEmpagliflozin52$46,252
Ranolazine ErRanolazine531$34,787
FarxigaDapagliflozin Propanediol39$27,010
Praluent PenAlirocumab41$22,622
CorlanorIvabradine Hcl13$15,903
Midodrine Hcl203$11,214
Flecainide Acetate309$7,127
Repatha SyringeEvolocumab13$7,105
Metoprolol Succinate527$6,020
Atorvastatin Calcium539$5,401

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$178$589,997742 claims
NovartisEntresto$316$305,481329 claims
Johnson & JohnsonXarelto$363$258,366267 claims
AstraZenecaBrilinta, Farxiga$52$126,052178 claims
Sanofi-aventis U.S. LLCMultaq$70$91,64889 claims
Boehringer IngelheimJardiance$138$46,25252 claims
AmgenCorlanor$42$15,90313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 130 cardiovascular disease providers in Arkansas.

Other cardiovascular disease in Fort Smith

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →